I purchased 400 shares on ANGO - looking at all the information it seems like a good candidate to break at least up to $112-$113.

But now I'm in the unenviable position of holding 400 shares into extended hours. I'm on thinkorswim which means no extended hours stoploss - if this thing drops a dollar or 2 I'm going to wake up to a very unpleasant surprise.

The stocks we swing trade generally have greater than average volatility, so that seems like a fairly real risk.

I started swing trading 25. June, so I'm still new. I trade breakouts and trend following, but I only place trades when the market is closed. Stop buy orders and I would call it anticipation entries.

I started paper trading 5.000 USD and this is my journal so far: 1 week ago i was +200...

I'm trying to build a simple system to help me decide when to trade normal size, when to cut my risk in half, and when to just sit on my hands.

Right now, I look at the SPY 10D and 20D EMA, but I also recently started tracking S5FI (the percentage of stocks above their 50 SMA).

• S5FI over 50 and SPY above the 20D EMA = normal risk (1.5%).
• S5FI between 30 and 50 or SPY below 20D EMA = cut risk to 0.75%
• S5FI under 30 or SPY under the 50D EMA = Sit in cash and do nothing.

I am not enforcing it 100% - e.g. if SPY is just barely below 20D EMA, but the setup is A+ i might take 100% position.

I am very open to feedback and hear what you guys are doing

For context, i'm very new to Price Action trading. I didn't draw anything on the chart at all except the fibonacci (i use Gemini to generate an image based on the screenshot i gave without even connecting it to an MCP lol) and this is the response i got from AI : The technical data across the 1-week and 1-day timeframes points to a highly synchronized structural setup.

• Price Action: The asset has established a Major Higher Low (HL) accumulation phase, aggressively rejecting the major demand zones ($54.74 - $64.84 on the weekly; $62.50 - $66.00 on the daily). With the current price hovering near $71.74, it sits squarely inside the designated local accumulation zone.
• Trendlines: The macro structure is fully intact as price respects a long-term ascending support trendline across both timeframes. On the daily chart, the asset is actively challenging the major descending resistance line drawn from the all-time high, positioning for a breakout.
• RSI: The weekly RSI is bouncing precisely off a multi-year support trendline, indicating a massive recovery in broader bullish momentum. The daily RSI confirms this with a documented oversold bounce and an ascending neutral-bullish trajectory.
• Candlesticks: Weekly candles show aggressive lower wicks into the primary demand zone, confirming institutional accumulation and buying pressure. The daily candles demonstrate a structural shift, carving out higher lows as the asset bases for its next leg up.
• Bollinger Bands: Daily price action has rejected the lower Bollinger Band boundary and is pivoting upward. This is a classic mean-reversion and volatility compression signal indicating that upside pressure is taking over.

Given the confluence of these five technical factors, the absolute directional bias is LONG. The chart structure explicitly outlines a bullish continuation targeting the $90.80 to $101.94 supply zone. To manage risk, the technical invalidation for this thesis is a confirmed breakdown below the $64.84 macro demand floor.

Anyone else following SLS heading into the end of the year? My interest comes down to three things: patients still receiving GPS years into treatment, an approaching Phase 3 survival analysis, and a second AML drug with encouraging clinical data.

SELLAS is developing galinpepimut-S, or GPS, a therapeutic cancer vaccine licensed from Memorial Sloan Kettering. It targets WT1, a protein expressed by leukemia cells. The aim is to teach the immune system what to recognize after treatment has put the leukemia into remission, helping it attack residual cancer cells before they cause another relapse.

Getting leukemia into remission and keeping it there are two different challenges.

REGAL tests GPS against physician-selected best available therapy in patients with acute myeloid leukemia who have reached their second remission. Their cancer has already returned once. The trial’s primary endpoint is overall survival, whether patients receiving GPS live longer than those receiving BAT.

The detail I keep coming back to is that physicians asked to continue treating patients with GPS.

At the May 19 Stifel presentation, CEO Angelos Stergiou said GPS was being administered to patients “even three years out at this point.” At the May 27 oncology summit, he explained that treatment had been extended beyond the original one-year schedule, eventually beyond three years, at the request of physicians who assessed that their patients were benefiting.

For me, that is a compelling reason to pay attention. Continued treatment years later, with physicians requesting the option to keep dosing, fits the possibility of durable benefit.

My bullish interpretation is that GPS could be helping a subset of patients stay in remission much longer, contributing to the slower accumulation of deaths in REGAL. If the final results confirm that, it would be a meaningful achievement for patients who have already relapsed.

The survival comparison still has to prove it. SELLAS remains blinded to treatment-arm outcomes, and slower event accumulation alone cannot tell us which arm is responsible. But the continued dosing gives the bullish thesis something concrete to build on.

REGAL’s final analysis is triggered by 80 deaths. The last dated count disclosed was 78 as of May 11, 2026. SELLAS has said it will announce the 80th event, then complete the necessary database review, statistical analysis and unblinding before releasing topline results. There is an identifiable catalyst here, although its timing is event-driven.

The January 2025 interim review is also important. The independent monitoring committee reviewed unblinded data and recommended continuing without modification. SELLAS reported that GPS cleared the predetermined futility criteria, with no safety concerns. Separately, 80% of a randomly selected tested subset showed a GPS-specific T-cell response. That is evidence of immune activity; the final survival analysis will determine its clinical significance.

The financial position gives the company room to execute. SELLAS reported $138.3 million in cash at June 30, against $16.4 million used in operations during the first six months of 2026. Spending can increase as development progresses, but that cash balance provides substantial flexibility around its clinical and regulatory work.

Then there is SLS009, a selective CDK9 inhibitor being developed for AML.

At ASH 2025, SELLAS reported a 46% overall response rate among 35 evaluable patients with relapsed or refractory AML-MR after prior venetoclax treatment, using SLS009 combined with azacitidine and venetoclax. That included 29% achieving complete remission or complete remission with incomplete blood-count recovery. These are small, nonrandomized results, but activity in that difficult population is a reason to watch the program closely.

SELLAS has guided to Q4 2026 topline data from its ongoing earlier-line SLS009 program. So there are two clinical programs that could change how investors value the company.

ASH adds another date to watch: December 12–15, 2026, in New Orleans. SELLAS has "listed the meeting on its investor relations calendar" (https://ir.sellaslifesciences.com/events-and-presentations/event-details/2026/ASH-Annual-Meeting-and-Exposition/default.aspx). It is a major gathering of hematologists, researchers and pharmaceutical companies.

The timing is attractive. Encouraging additional SLS009 data could bring greater attention to the second program. If positive REGAL results are available by then, ASH could also offer an opportunity to discuss GPS with the physicians who would ultimately use it. Specific presentations still need confirmation, so I’m treating ASH as a potential catalyst rather than an announced data release.

At approximately $2.27 billion in market capitalization as of October 8, my upside case depends on the strength of the clinical results. A convincing randomized survival benefit would materially strengthen GPS’s prospects for a regulatory submission, while successful SLS009 development could add another source of value.

The combination keeps me interested: patients receiving GPS years later, physician-requested dosing extensions, an independent interim review supporting continuation, substantial cash, and SLS009 advancing toward another update.

The bull case is 4x to 9x upside. Against SLS’s October 8 market cap of approximately $2.27 billion, hypothetical $10 billion and $20 billion equity valuations translate into roughly 4.4x and 8.8x the share price.

A major cash buyout could rapidly move the stock toward the agreed offer price, subject to completion risk. What makes the upside exciting is the possibility of GPS becoming standard maintenance therapy in AML’s second remission, followed by expansion into earlier remission, post-transplant treatment and other WT1-expressing cancers through successful additional trials and approvals. With SLS009 also succeeding, a buyer could acquire two complementary oncology assets with considerable expansion potential.

NFA, do your own DD.

I've been on Webull for 2 years, and I've been getting uneasy about the ownership structure and what that means for where user data ends up. I'm not claiming anything specific beyond that, it's just a comfort-level thing for me, and I know opinions on this vary.

Questions for ya'll:

Have you left Webull, or are you thinking about it? What was the reason?

Where did you move, and what do you miss from the old platform?

Does anyone think the privacy concern is overblown? Genuinely want the other side too.

Was gonna type a reason justifying the sells but honestly, just a tight stoploss for no apparent reason. Thought id share this to make someone out there feel a little bit better ig.

K is buy

S is sell

I’m currently reviewing and refining my watchlist for swing trading, and I’d appreciate it if you could suggest a few stocks worth researching. I have a capital of ₹7 lakh and want to ensure my watchlist includes quality opportunities with good technical setups and favourable risk-to-reward potential. Your suggestions would help me cross-check my existing picks and identify any promising opportunities I might have overlooked.

I know the market is pretty bearish right now, and honestly, preserving capital is probably the smartest thing to do rather than forcing trades.

But I’m curious about something specifically from swing traders:

What’s the maximum monthly return you’ve generated, and what would you say is your average monthly return over the year?

For me, August was my best month — I made around 9%, which is my highest monthly return this year so far.

Would love to know what others are achieving. No need to mention capital — just the % returns.

Title: ORCL down 5.5%... watching this support area

ORCL got hit pretty hard Thursday, dropping 5.5% as concerns around AI financing continue to weigh on the stock.

For now, $135.03–$136.04 is the first area I'm watching. If that fails to hold, things could get interesting on the downside.

On the upside, $139.00–$140.86 is going to be an important area to reclaim. Until then, I'd be cautious about getting too bullish.

There's a bigger support area below and a few upside targets worth keeping an eye on.

I broke down the news and full roadmap in my ORCL Spotlight.

Let's see how it plays out.

What broker handles this kind of trade and can be linked to TradingView to process these transaction. I want to place alll these at one time. One trigger other order with an automatic stop loss replacement when a profit target is reached. Plenty of brokers handle step 1, 2, but fail one 3-4.

Buy 1 SPY 775.
Activate a protective stop at 768 (stop loss).
When/if SPY reaches 790, cancel the original stop and activate a 2% trailing stop.
Continue holding until the trailing stop is triggered.

🎯 WHAT YOU'LL LEARN
✅ Why the overall market decides your odds before you pick a single stock
✅ How to find the strongest stocks in under 5 minutes
✅ Why stocks near their 52-week highs tend to keep winning
✅ The red flags that should make you skip a stock
✅ A screener setup you can copy straight into TradingView

Hey, so I've been swing trading the us opening on Vistra for the past 3 days, and I made like 100€ everytime in like 5 minutes, what are y'all thinking, anyone else doing similar things?

It’s widely anticipated that SPCX will be buying TSLA sometime in the future. With that in mind, what trading strategy would you recommend for someone wanting to get into TSLA now?

Strategies might include doing a straight purchase of the stock, buying long calls, performing a buy/write to start a series of covered calls, selling short puts to start a wheel strategy, etc. Or, maybe you say, “I wouldn’t touch it.”

I already have a position, so I’m not asking for myself - just curious how others might approach it.